Welcome to SpyGlass Ophthalmics
A vision towards a higher quality of life!
Welcome to SpyGlass Ophthalmics
A vision towards a higher quality of life!
A vision towards a higher quality of life!
A vision towards a higher quality of life!
SpyGlass Ophthalmics (SGO), a privately-held ophthalmic therapeutics company announced that it has secured $27.5 million in Series B financing. The financing, which was led by Vensana Capital alongside existing investor New Enterprise Associates (NEA), will enable the company to further advance development efforts of platform technology that has the potential to address several unmet needs across a range of chronic ophthalmic diseases.
SpyGlass Ophthalmics (SGO) has partnered with New Enterprise Associates (NEA) to support the development of novel technologies with a vision towards a higher quality of life. The funding will be used to achieve SGO’s research, development and clinical targets.
Copyright © 2019 SpyGlass Ophthalmics - All Rights Reserved.
Powered by GoDaddy Website Builder